Methods. Sera from 36 patients with JDM were analyzed. Autoantibody profiles were determined by probing microarrays, which were fabricated with ϳ80 distinct autoantigens, with serum and a Cy3-conjugated secondary antibody. Arrays were scanned and analyzed to determine antigen reactivity. Serum IFN␣ activity was measured using a functional reporter cell assay. Sera were assayed alone or in combination with cellular material released from necrotic U937 cells to stimulate peripheral blood mononuclear cells from healthy donors in vitro, and IFN␣ production in culture was measured by a dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA).
(ANAs), although the ANA specificity remains unknown for most patients (4) .
Type I interferons (IFNs) appear to play a role in JDM. Transcript profiling of muscle tissue from untreated patients with JDM demonstrated increased expression of several type I IFN-inducible genes (5) . Transcript profiling has also shown up-regulation of type I IFN-inducible genes in peripheral blood mononuclear cells (PBMCs) from patients with JDM (6) . Comparison of transcript profiles of PBMCs from healthy children, patients with JDM, and patients with pediatric systemic lupus erythematosus (SLE) demonstrated up-regulation of type I IFN-regulated transcripts in 50% of the patients with active JDM, and this type I IFN signature overlapped with, but was distinct from, the type I IFN signature identified in patients with pediatric SLE (6) . In addition, IFN␣ activity in sera from untreated patients with JDM was increased compared to that in sera from age-matched controls (7) . Furthermore, sera from adult myositis patients with Jo-1 or Ro 52/Ro 60 autoantibodies induced IFN␣ production in healthy donor PBMCs (8) . Those studies suggest that both type I IFN proteins and IFN-inducible genes are up-regulated in myositis and may be critical in disease pathogenesis.
Autoantigen microarrays allow the comprehensive evaluation of autoantibodies directed against dozens of autoantigens using microliter quantities of serum (9) . Antibody binding to autoantigens on microarrays has been shown to be 4-8 times more sensitive than enzyme-linked immunosorbent assays (ELISAs), with specific antibody binding demonstrated over a 1,000-fold range (10) . The purpose of this pilot study was to characterize the autoantibodies present in the sera of patients with JDM using autoantigen microarrays and to determine whether serologic IFN␣ activity correlates with the presence of specific autoantibodies.
PATIENTS AND METHODS
Patients. Thirty-six patients (28 females and 8 males with a median age of 10.5 years) with definite/probable JDM (based on the Bohan and Peter criteria) and 10 controls (with a median age of 11 years) were included in the study. Patient demographics and clinical characteristics at the time of sample collection are shown in Supplementary Table 1 (available on the Arthritis & Rheumatism web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.38038/abstract). Skin and muscle disease activity were evaluated using the validated Disease Activity Score (DAS) (11) . The Institutional Review Board at the Ann and Robert H. Lurie Children's Hospital of Chicago Research Center approved the study (IRB #2002-11762), and age-appropriate informed consent was obtained. Sera from 10 of the patients with JDM (28%) were positive for myositis-specific autoantibodies (MSAs) or myositis-associated autoantibodies (MAAs), including antiRo, anti-Mi-2, anti-U1 RNP, anti-U2 RNP, anti-Scl-70, anti-PM-Scl, and anti-signal recognition particle (12) .
Autoantigen microarrays. Autoantigen microarrays were generated by spotting distinct autoantigens in replicates using a VersArray ChipWriter Pro microarrayer (Bio-Rad) with a customized printhead and Silicon Microarray Spotting Pins (Parallel Synthesis Technologies) as previously described (10) . A complete list of these autoantigens is provided in Supplementary art.38038/abstract). Microarrays were probed with 1:150 dilutions of serum and a Cy3-conjugated goat anti-human IgG/IgM secondary antibody (Jackson ImmunoResearch) using protocols established in our laboratory (13) . Arrays were scanned using a GenePix 4000 scanner (Molecular Devices). Digital images were collected and stored in a database for analysis. Reporter cell assay. Reporter cells (WISH epithelial cell line) were cultured for 6 hours with sera from patients with JDM, lysed, and RNA was isolated. Real-time quantitative polymerase chain reaction was used to measure the relative expression of 3 IFN␣-induced genes (IFN-induced protein with tetratricopeptide repeats 1, myxovirus resistance protein 1, and RNA-dependent protein kinase) in the reporter cells (14) . Relative expression data from these transcripts were normalized using the mean and SD of healthy donor sera (n ϭ 10) that were run in the same assay, and data are presented as an IFN␣ activity score. The serum-induced reporter cell activity can be blocked with anti-IFN␣ monoclonal antibodies, and no significant functional inhibitors have been detected (14) .
IFN␣ inducers and culture of PBMCs. PBMCs from healthy donors were cultured in 96-well plates with 4 different concentrations of patient or healthy control sera, ranging from 0.001% to 1%, alone or in combination with 10% necrotic material from U937 cells. Each serum sample was used to stimulate PBMCs from 2 healthy donors. Ultraviolet lightinactivated herpes simplex virus type 1 and serum from an SLE patient were used as positive controls. After 20 hours, IFN␣ levels in the cell culture supernatants were measured by a dissociation-enhanced lanthanide fluoroimmunoassay (15) . The cutoff level, based on the level induced by the healthy control sera, was set at 21 units/ml.
Statistical analysis. For the autoantigen microarrays, quantitative analysis of the fluorescence intensity of individual features was performed using GenePix Pro software version 6.1 (Molecular Devices). The fluorescence intensity of each feature was determined based on the median pixel intensity within the circumscribed antigen feature minus the background. The median fluorescence intensity minus background (MFI-B) was calculated for each antigen. For each individual sample from patients with JDM, reactivity against an antigen was considered to be significant if the MFI-B for the antigen was more than 3 SD above the mean MFI-B for that antigen in the 10 control samples.
Significance Analysis of Microarrays (SAM) was used to determine differences between patients with JDM and controls and to perform subgroup analyses among the patients with JDM. SAM is an interactive algorithm developed at Stanford University that assigns a standardized score to each protein recognition event, and antigens with scores higher than an adjustable threshold are considered "potentially significant." SAM can be used to correlate array data with clinical, demographic, and treatment data. SAM is described fully at http://www-stat.stanford.edu/ϳtibs/SAM (16) .
Comparisons of the proportions of patients who were positive for particular autoantibodies and had a positive type I IFN assay were performed using Fisher's exact test, with P values calculated by the sum of small p's method. Odds ratios were calculated using standard methodology.
RESULTS
Evaluation of the MFI-B for each patient with JDM compared to the mean MFI-B of controls revealed that 27 patients with JDM (75%) had reactivity against at least 1 of 41 antigens on the microarray (Table 1) . The number of patients with reactivity against each of these antigens ranged from 1 (3%) to 6 (17%). The majority of sera demonstrated reactivity against one or two antigens while some sera had a broader spectrum of reactivity (Table 1) .
Two MSAs, anti-Mi-2 and anti-PL-12, and several MAAs, including anti-La, anti-Ro 52, anti-Ro 60, anti-U1 RNPs, and anti-Ku antibodies, were identified in this JDM cohort ( Table 1) . Several of the other reactivities observed were against autoantigens associated with SLE, including histones, Sm, and proliferating Figure 1 . Interferon-␣ (IFN␣) activity and production in sera from patients with juvenile dermatomyositis (JDM). A, Serum IFN␣ activity in patients with JDM and healthy controls, as determined by reporter cell assay. Each data point represents an individual subject; horizontal lines and error bars show the median and interquartile range. B, In vitro IFN␣ production in normal peripheral blood mononuclear cells (PBMCs) stimulated with necrotic cell material combined with sera from patients with JDM. Each data point represents the mean IFN␣ production in PBMCs from 2 healthy blood donors in response to serum from an individual patient. The horizontal line represents the median IFN␣ production for the JDM cohort. Samples with IFN␣ production above 21 units/ml (broken line) were considered positive based on assays run with healthy donor serum. cell nuclear antigen (PCNA) ( Table 1 ). There was a correlation between ELISA results and microarray data in the sera from patients with JDM for Ro 52, Ro 60, and La, with Spearman's r values ranging from 0.44 to 0.63 (data not shown).
SAM did not reveal any significant difference in autoantibody reactivity between sera from patients with JDM as a whole and control sera. Similarly, the results of SAM subgroup analyses of ANA-positive versus ANA-negative patients, patients with high (Ն3) versus those with low (Յ2) skin or muscle DAS, and patients with versus those without a family history of SLE were not significant (data not shown).
Given that PBMCs from a subset of patients with JDM have an IFN signature, we used a reporter cell assay to further characterize sera from this JDM cohort for the ability to induce IFN␣ activity (14) . Of the JDM patient sera assayed, most did not induce up-regulation of the IFN␣-regulated genes, 2 induced high IFN␣ activity (ϩϩϩ), and 5 induced low activity (ϩ), as shown in Figure 1A and Table 2 . Typical values for normal pediatric and adult sera are between 0 and 2.
There was an association between the induction of serum IFN␣ activity in the reporter cell assay and positivity for anti-Ro, anti-La, anti-Sm, or anti-PCNA specificities. Serum IFN␣ activity was induced by sera Table 1 for definitions. † Determined by reporter cell assay. Ϫ ϭ no interferon-␣ (IFN␣) activity; ϩ ϭ low IFN␣ activity; ϩϩϩ ϭ high IFN␣ activity. ‡ Determined by dissociation-enhanced lanthanide fluoroimmunoassay. Ϫ ϭ no IFN␣ production; ϩ ϭ low IFN␣ production; ϩϩϩ ϭ high IFN␣ production. § Ϫ ϭ not reactive; ϩ ϭ reactive. ¶ Nucleic acid-associated antigen. from 6 of the 13 patients who were positive for 1 of these autoantibodies versus only 1 of the 23 patients who were negative for these antibodies (P ϭ 0.005). Similarly, there was an association between serum IFN␣ activity and autoantibody positivity in patients with reactivity against any DNA-associated antigen, with serum from 6 of the 16 patients who were positive for 1 of these antibodies inducing serum IFN␣ activity, as compared to serum from only 1 of the 21 patients who were negative for these antibodies (P ϭ 0.039). The 2 serum samples with high IFN␣ activity also had strong reactivity against components of the Sm/RNP complex, and all of the samples with IFN␣ activity in the reporter cell assay demonstrated reactivity against at least 1 nucleic acidassociated autoantigen (Table 2 ). SAM identified increased reactivity against several of these antigens, including Ro 52, Sm/RNP, U1-C, and Mi-2, in sera positive for the receptor cell assay (data not shown).
Previous studies have demonstrated that SLE sera combined with apoptotic U937 cells induce healthy donor PBMCs to produce IFN␣ in vitro (15) . We evaluated sera from patients in this JDM cohort for the ability to induce IFN␣ production using this assay. Sixteen serum samples induced IFN␣ production and thus had the capacity to generate interferogenic immune complexes, as seen in Figure 1B . There was an association between IFN␣ production and reactivity against Ro, La, Sm, and RNP antigens (P ϭ 0.034). In addition, several of the 16 positive samples demonstrated reactivity against other nucleic acid-associated antigens, including Ro 52, La, CENP-B, Mi-2, and components of the Sm/RNP complex ( Table 2) . SAM identified increased reactivity against Ro 60 in sera positive for this assay (data not shown).
DISCUSSION
This is the first study to evaluate autoantibody reactivity against a large number of antigens in JDM using antigen microarrays. Using the stringent cutoff of MFI-B greater than 3 SD above the mean MFI-B in the control group to determine significant reactivity, we demonstrated an unexpectedly broad spectrum of autoantibodies in this JDM cohort. These included MSAs and MAAs, autoantibodies classically associated with SLE and other autoimmune diseases, as well as other autoantibodies not previously described in JDM. The frequency of MSAs in our cohort was similar to that found in previous studies, while our cohort had an increased frequency of certain MAAs, including antiRo, anti-La, and anti-U1 RNP (17) . This likely reflects the increased sensitivity of the antigen microarrays compared to standard immunoassays such as ELISA (10) .
Despite the presence of autoantibody reactivity in the majority of sera from patients with JDM, it is not surprising that SAM did not identify reactivity that distinguished the JDM cohort as a whole from the control subjects or that distinguished between ANApositive and ANA-negative subgroups of JDM patients, due to the small percentage of patients with reactivity against any given antigen (3-17%) ( Table 1) . Interestingly, many of the autoantibodies identified were directed against nuclear antigens, and these reactivities could be the source of the positive ANAs without known specificity. However, these reactivities do not account for all 72% of the ANA positivity in this cohort, suggesting that additional nuclear antigens not present on our microarray are likely present in some patients with JDM. This is a known limitation of antigen microarray technology, which is a biased assay that only detects reactivity to the predetermined antigens printed on the microarray. In particular, the microarrays manufactured for this study did not include the p155/140 antigen that was recently identified in Ͼ20% of patients with JDM (18) .
This study demonstrated that sera from some patients with JDM had the ability to induce IFN␣ activity or production in two in vitro assays (Figure 1 ). In fact, there was a correlation between the presence of antibodies against RNA-containing autoantigens and both serum IFN␣ activity and the capacity to generate interferogenic immune complexes. In particular, SAM identified Ro 52 and Ro 60 reactivity as being significantly associated with the ability of the sera to induce IFN␣ production in vitro, and Ro 52, Sm/RNP, and U1-C reactivity was associated with IFN␣ activity in the reporter cell assay. Consequently, antibodies to RNAbinding proteins seem to be critical elements in the process that leads to increased IFN␣ production in a subset of patients with JDM. However, there are some limitations of this study. For example, given that the family history of SLE is increased 5 times above background in children with JDM and is associated with increased IFN␣ activity (19) , it is possible that unrecognized family linkages might be the source of the low levels of La, Ro 52, and Ro 60. Still, SAM did not identify an increased reactivity to any antigens when comparing JDM patients with a family history of SLE to those without a family history of SLE (data not shown).
In conclusion, a broad spectrum of autoantibodies is produced in patients with JDM, and sera with antibodies directed against RNA-containing autoantigens induce IFN␣ activity or production in vitro. We hypothesize that RNA-containing autoantigens, including Ro, La, Sm, and RNP, play a critical role in the activation of the type I IFN system in JDM and are an essential component of the autoimmune disease process. Further studies are needed to elucidate the mechanisms by which this activation contributes to the pathogenesis of JDM.
